Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

CDC Publications

Drug Overdose Deaths involving Cocaine and Psychostimulants with Abuse Potential – United States, 2003-2017

This report analyzes the impact and demographic variation of drug overdose deaths involving cocaine and psychostimulants, showing death rates have increased across age groups, racial/ethnic groups, county urbanization levels, census regions, and multiple states. Death rates involving cocaine and psychostimulants with and without opioids have increased. Synthetic opioids appear to be the primary driver of cocaine-involved death rate increases, and recent data point to increasing synthetic opioid involvement in psychostimulant-involved deaths. Increases in deaths involving cocaine and psychostimulants with and without opioids in recent years illustrates the growing complexity of America’s current overdose crisis.

Read More

2019

2018

2017

2016

2015

2014

2013

2012

2011

2006 – 2010

  • Toblin RL, Paulozzi LJ, Logan JE, Hall AJ, Kaplan JA.  Mental illness and psychotropic drug use among prescription drug overdose deaths: a medical examiner chart review J Clin Psych. 2010;71: 491-496.

thumbnail image of PDF

Annual Surveillance Report of Drug-Related Risks and Outcomes – United States, 2018 [PDF – 2MB]

  • Summarizes the latest information available for various health outcomes, health behaviors, and prescribing patterns related to the drug problem in the United States. This report covers latest data available on rates of opioid prescribing, substance use disorder, nonfatal hospitalizations and emergency department visits, and overdose deaths. National information, and some state information, is presented to serve as a resource to help address the ongoing national problem of drug abuse, addiction, and overdose.

thumbnail image of PDF

Highlights from the Annual Surveillance Report of Drug-Related Risks and Outcomes – United States, 2018 [PDF – 5 MB]

Presentation available for download, and includes highlights of the data, maps, tables, and charts from the second Annual Surveillance Report of Drug-Related Risks and Outcomes – United States.  Citation when using resources from this presentation [Centers for Disease Control and Prevention. 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States. Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published August 31, 2018. Accessed 08/31/2018 from  www.cdc.gov/drugoverdose/pdf/pubs/CDC_2018_Surveillance-Report_DataSummary_presentation.pdf

NCHS Data Publications

MMWR has an opioid series prepared by CDC providing weekly reports, surveillance summaries, and supplements on all public health topics from across the agency. Additional cross-cutting MMWR reports on opioids can be found here.

More

2019

2018

2017

2016

2015

2014

2010-2013

2004-2009

Increase in overdose deaths involving synthetic opioids other than methadone linked to increase in supply of fentanyl in PBSS states [PDF – 512 KB]

From 2010 to 2015, annual overdose deaths involving opioids in the United States increased by nearly 57%, with a notable rise in deaths attributed to synthetic opioids other than methadone. A new Prescription Behavior Surveillance System (PBSS) Issue Brief compares trends in synthetic opioid overdose deaths in five states. The data show a close association between rising synthetic opioid overdose deaths and the rising availability of illicitly manufactured fentanyl.

Geographic Patterns in Neonatal Abstinence Syndrome and Prescription Opioids in Kentucky [PDF – 809K]

Data released by the Commonwealth of Kentucky examines the relationship between rates of Neonatal Abstinence Syndrome (NAS) in various regions of the state versus risky opioid prescribing behaviors observed in these same regions. In the wake of the ongoing opioid epidemic, NAS has greatly increased nationwide, more than tripling from 2004 to 2013. Findings in Kentucky reveal a close association between NAS and high opioid prescribing rates in the preceding year among women of childbearing age.

Patient Risk Measures for Controlled Substance Prescriptions in Washington, 2013 [PDF – 877K]

An analysis of Washington prescription drug monitoring program (PDMP) data revealed that multiple provider episodes (MPEs) vary by age group and class of prescription drug. Opioids and opioid combinations had the highest number of days of overlapping prescriptions, and eight opioids had a mean daily dosage greater than 120 morphine milligram equivalents (MME). Findings indicate that MPEs, overlapping prescription, and mean daily dosages over 100 MMEs are patient risk factors to look for in PDMP data.

Maine’s PDMP data was analyzed to examine several patient risk measures for prescription drug misuse, abuse and overdose. Patients aged 35-54 had the highest rate of MPEs, and opioids were the drug class most frequently involved with MPEs. However, the rate of MPEs declined from 2010 to 2014, and this coincided with an increase in prescribing of buprenorphine, widely used in treating opioid dependence.

TOP